Second Waiver and Amendment to the Securities Purchase Agreement, dated as of March 30, 2018, , dated October 16, 2017, by and among the Registrant, Myovant Holdings Limited, Myovant Sciences GmbH, Myovant Sciences Ireland Limited, Myovant Sciences, Inc., the Purchasers (as defined therein) and NovaQuest Pharma Opportunities Fund IV, L.P

This Second Waiver and Amendment to Securities Purchase Agreement (the “Waiver and Amendment”) is entered into as of the 30th day of March 2018, by and among Myovant Sciences Ltd., an exempted company incorporated and organized under the laws of Bermuda (“Issuer”), Myovant Holdings Limited, a company incorporated in England and Wales with registered number 10317663 (“Myovant England”), Myovant Sciences GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (“Myovant Switzerland”), Myovant Sciences Ireland Limited, a private company limited by shares organized under the laws of Ireland with registered number 601541 (“Myovant Ireland”), Myovant Sciences, Inc., a Delaware corporation (“Myovant Delaware” and, together with Myovant England, Myovant Switzerland and Myovant Ireland, each a “Guarantor”, and together with Issuer, collectively, the “Note Parties”), the several banks and other financial institutions or entities from time to time parties to the Purchase Agreement (as defined below) (each referred to as a “Purchaser” and collectively referred to as “Purchasers”), and NOVAQUEST PHARMA OPPORTUNITIES FUND IV, L.P., a Cayman Islands exempted limited partnership, in its capacity as administrative agent and collateral agent for itself and Purchasers (in such capacity, the “Agent”).

WHEREAS, the Note Parties, Agent and Purchasers    have entered into that certain Securities Purchase Agreement dated as of October 16, 2017 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), pursuant to which Purchasers have agreed to purchase certain Notes from Issuer in accordance with the terms thereof; and

WHEREAS, clause (iii) of Section 2.01(f) of the Purchase Agreement states that “to the extent that the Notes have not been listed and admitted to trading on the BSX (or another recognized stock exchange within the meaning of Section 1005 Income Tax Act 2007) prior to the first scheduled interest payment date, the payment of any amount of interest which would have been due and payable on such date shall be deferred until the next Business Day after the second scheduled interest payment date (the “Initial Payment Extension Provision”); and

WHEREAS, on March 22, 2018, Issuer submitted its listing application to the BSX in full, but does not expect the listing to be admitted until up to fifteen days after the second scheduled interest payment date; and

WHEREAS, Section 11.03(b) of the Purchase Agreement provides that the Note Parties, the Agent and the Required Purchasers may, by written consent, (i) waive certain requirements of the Purchase Agreement and (ii) amend the Purchase Agreement; and

WHEREAS, the Note Parties, the Agent and the Required Purchasers desire to waive the Initial Payment Extension Provision and amend Section 2.01(f)(iii) to extend such provision by fifteen days; and

WHEREAS, the Note Parties, the Agent and the Required Purchasers desire to amend the Purchase Agreement pursuant to this Waiver and Amendment to modify the first date on which the payment of interest on the Notes must be paid; and

WHEREAS, the undersigned constitute all of the Note Parties, the Agent and the Required Purchasers.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants, conditions and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows.

1.Defined Terms. Capitalized terms used herein (including in the preamble and recitals above) but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Purchase Agreement.

2.    Waiver. Subject to the terms and conditions of this Waiver and Amendment, Agent and the Required Purchasers hereby waive the Initial Payment Extension Provision to the extent the payment of any amount of interest would be due and payable on the next Business Day after the second scheduled interest payment date. The foregoing waiver is a limited, one-time waiver and, except as expressly set forth herein, shall not be deemed to: (a) constitute a waiver of any other provision or Event of Default under the Purchase Agreement or any other Note Document, whether now existing or hereafter arising, (b) constitute a waiver of any right or remedy of Agent or any Purchaser under the Purchase Agreement or any other Note Document, or (c) establish a custom or course of dealing or conduct between Agent and Purchasers, on the one hand, and any Note Party on the other hand with respect to the waiver of any other provision under the Purchase Agreement or any other Note Document. The foregoing waiver shall not be deemed to constitute a consent of any other act, omission or any breach of the Purchase Agreement or any of the other Note Documents.

3.    Amendment to Purchase Agreement. Subject to the satisfaction of the conditions precedent set forth herein, Section 2.01(f)(iii) of the Purchase Agreement is hereby deleted in its entirety and the following language is hereby substituted therefor:

4.    Conditions. The effectiveness of this Waiver and Amendment is subject to the satisfaction of the following conditions precedent:

(a)    the execution and delivery of this Waiver and Amendment by the Note Parties, Agent and Required Purchasers, together with such other documents and instruments reasonably requested by Agent; and

(b)    no Event of Default shall have occurred and be continuing.

5.    No Modification. Except as expressly stated herein, the Agent and Purchasers reserve all rights, privileges and remedies under the Note Documents. Except as amended or consented to hereby, the Purchase Agreement and other Note Documents remain unmodified and in full force and effect. All references in the Note Documents to the Purchase Agreement shall be deemed to be references to the Purchase Agreement as amended hereby.

6.    Successors and Assigns. The provisions of this Waiver and Amendment shall inure to the benefit of and be binding on each Note Party and its permitted assigns (if any), except that no Note Party shall assign its obligations hereunder or under any of the other Note Documents without Agent’s express prior written consent, and any such attempted assignment shall be void and of no effect.

7.    Governing Law. This Waiver and Amendment shall be governed by and construed under the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

8.    Reaffirmation of Obligations. Each Note Party (a) acknowledges and consents to all of the terms and conditions of this Waiver and Amendment, (b) affirms all of its obligations under the Note Documents and (c) agrees that this Waiver and Amendment does not operate to reduce or discharge such Note Party’s obligations under the Note Documents.

9.    Reaffirmation of Security Interests. Each Note Party (a) affirms that each of the Liens granted in or pursuant to the Note Documents are valid and subsisting and (b) agrees that this Waiver and Amendment shall in no manner impair or otherwise adversely affect any of the Liens granted in or pursuant to the Note Documents.

10.    Counterparts. This Waiver and Amendment may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Waiver and Amendment to Securities Purchase Agreement as of the day and year first above written.

NOVAQUEST PHARMA OPPORTUNITIES FUND IV, L.P.

NOVAQUEST PHARMA OPPORTUNITIES FUND IV, L.P.

NOVAQUEST PHARMA OPPORTUNITIES FUND IV (PARALLEL), L.P.